SCHEMBL2007390

SCHEMBL2007390

Oc1cc(O)cc(OCc2ccccc2)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.67
CYP1A1 P04798 1/20 0.67
CYP19A1 P11511 1/20 0.67
LMNA P02545 1/20 0.67
PTGS1 P23219 1/20 0.67
SLC6A2 P23975 1/20 0.67
CYP2C19 P33261 1/20 0.67
PTGS2 P35354 1/20 0.67
SLC6A3 Q01959 1/20 0.67
HIF1A Q16665 1/20 0.67
HDAC6 Q9UBN7 1/20 0.67
MEN1 O00255 1/20 0.61
KMT2A Q03164 1/20 0.61
ALOX5 P09917 1/20 0.57
CYP4F2 P78329 1/20 0.55
CYP4A11 Q02928 1/20 0.55
MAOB P27338 7/20 0.53
GAA P10253 1/20 0.53
MAPT P10636 1/20 0.53
MAOA P21397 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1834526 0.96 CYP1A2 (0.67) CYP1A2CYP1A1CYP19A1LMNAPTGS1
SCHEMBL31183087 0.87 CYP1A2 (0.58) CYP1A2CYP1A1CYP19A1LMNAPTGS1
SCHEMBL29142397 0.87 CYP1A2 (0.58) CYP1A2CYP1A1CYP19A1LMNAPTGS1
SCHEMBL2808909 0.87 GPBAR1 (0.58) CYP1A2CYP1A1CYP19A1LMNAPTGS1
SCHEMBL5791635 0.87 MAOB (0.69) CYP1A2CYP1A1CYP19A1LMNAPTGS1
SCHEMBL4516341 0.87 CYP1A2 (0.58) CYP1A2CYP1A1CYP19A1LMNAPTGS1
SCHEMBL31418062 0.87 MAOB (0.64) CYP1A2CYP1A1CYP19A1LMNAPTGS1
SCHEMBL30994413 0.87 CYP1A2 (0.58) CYP1A2CYP1A1CYP19A1LMNAPTGS1
SCHEMBL16886123 0.87 CYP1A2 (0.58) CYP1A2CYP1A1CYP19A1LMNAPTGS1
SCHEMBL28298170 0.87 CYP1A2 (0.58) CYP1A2CYP1A1CYP19A1LMNAPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10344215-B2 Polymerizable compounds and the use thereof in liquid-crystal displays MERCK PATENT GMBH (DE) 2019-07-09 US disclosed
US-7964628-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-06-21 US disclosed
US-7964628-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-06-21 US disclosed
US-7964628-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-06-21 US disclosed
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-10-07 US disclosed
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-10-07 US disclosed
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-10-07 US disclosed
US-7759387-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-07-20 US disclosed
US-7759387-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-07-20 US disclosed
US-7759387-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-07-20 US disclosed
US-20070021489-A1 Fibrinogen receptor antagonists and their use NICHOLAS PIRAMAL INDIA LIMITED (IN) 2007-01-25 US disclosed
US-20070021489-A1 Fibrinogen receptor antagonists and their use NICHOLAS PIRAMAL INDIA LIMITED (IN) 2007-01-25 US disclosed
US-20070021489-A1 Fibrinogen receptor antagonists and their use NICHOLAS PIRAMAL INDIA LIMITED (IN) 2007-01-25 US disclosed
EP-1677783-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE Nicholas Piramal India Limited (IN) 2006-07-12 EP disclosed
WO-2005035495-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE NICHOLAS PIRAMAL INDIA LIMITED (IN) 2005-04-21 WO disclosed
WO-2005035495-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE NICHOLAS PIRAMAL INDIA LIMITED (IN) 2005-04-21 WO disclosed
US-4847236-A Recording material FUJI PHOTO FILM CO., LTD. (JP) 1989-07-11 US disclosed
EP-0272099-A2 Color-forming sheet recording material FUJI PHOTO FILM CO., LTD. (JP) 1988-06-22 EP disclosed
US-3998782-A AGAINST HEAT AKZO N.V. (NL) 1976-12-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE FGB, F13B, F2 CYP1A2 742/4885CYP1A1 1034/4885CYP19A1 2732/4885
US-10344215-B2 Polymerizable compounds and the use thereof in liquid-crystal displays VCL, PLEC, EML4 CYP1A2 3876/4885CYP1A1 4571/4885CYP19A1 3715/4885
US-20070021489-A1 Fibrinogen receptor antagonists and their use FGB, F13B, F2 CYP1A2 742/4885CYP1A1 1034/4885CYP19A1 2732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.